AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...
BioSpace4d
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Why AstraZeneca Topped the Market on Thursday
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growth
Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...
AstraZeneca reports Q4 core EPS $2.09
Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...
Pharmaceutical Technology on MSN4d
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
precisionmedicineonline4d
AstraZeneca Optimistic About Phase III Capivasertib Data in 2025, Reports Strong Q4 Product Growth
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.